Literature DB >> 8323768

Prognostic factors in malignant gliomas with special reference to intra-arterial chemotherapy.

K Watne1, E Hannisdal, O Nome, B Hager, H Hirschberg.   

Abstract

Survival was analyzed in 173 patients with malignant gliomas to study the importance of possible pretreatment prognostic factors. Seventy-nine of these patients received preirradiation intra-arterial chemotherapy with BCNU combined with vincristine intravenously and procarbazine orally; the others received only postoperative whole-brain irradiation. To judge by univariate and multivariate analyses the most important pretreatment prognostic factors were histology, corticosteroid dependency, pretreatment performance status and frontal lobe location of the tumors. Patients with anaplastic astrocytoma, not corticosteroid-dependent, with pretreatment performance status of 0-2 and with a frontal lobe location of the tumor seemed to benefit most from preirradiation chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8323768     DOI: 10.3109/02841869309093600

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  9 in total

1.  The conditional survival statistics for survivors with primary supratentorial astrocytic tumors.

Authors:  S L Hwang; Y H Yang; A S Lieu; M C Chuang; S J Chang; Y Y Chang; H J Lin; S L Howng
Journal:  J Neurooncol       Date:  2000-12       Impact factor: 4.130

Review 2.  Clinical Relevance of Steroid Use in Neuro-Oncology.

Authors:  K Ina Ly; Patrick Y Wen
Journal:  Curr Neurol Neurosci Rep       Date:  2017-01       Impact factor: 5.081

3.  A population-based study of high-grade gliomas and mutated isocitrate dehydrogenase 1.

Authors:  Rikke H Dahlrot; Bjarne W Kristensen; Jacob Hjelmborg; Jørn Herrstedt; Steinbjørn Hansen
Journal:  Int J Clin Exp Pathol       Date:  2012-11-20

4.  Predicted and actual BCNU concentrations in normal rabbit brain during intraarterial and intravenous infusions.

Authors:  S J Hassenbusch; J H Anderson; O M Colvin
Journal:  J Neurooncol       Date:  1996-10       Impact factor: 4.130

5.  Impact of postoperative dexamethasone on survival, steroid dependency, and infections in newly diagnosed glioblastoma patients.

Authors:  Akshitkumar M Mistry; Sumeeth V Jonathan; Meredith A Monsour; Bret C Mobley; Stephen W Clark; Paul L Moots
Journal:  Neurooncol Pract       Date:  2021-06-23

6.  Steroid management in newly diagnosed glioblastoma.

Authors:  Mariel B Deutsch; Katherine S Panageas; Andrew B Lassman; Lisa M Deangelis
Journal:  J Neurooncol       Date:  2013-03-06       Impact factor: 4.130

Review 7.  Intra-arterial chemotherapy of primary brain tumors.

Authors:  Herbert B Newton
Journal:  Curr Treat Options Oncol       Date:  2005-11

8.  Identification of a Dexamethasone Mediated Radioprotection Mechanism Reveals New Therapeutic Vulnerabilities in Glioblastoma.

Authors:  Paula Aldaz; Jaione Auzmendi-Iriarte; Maika Durántez; Irene Lasheras-Otero; Estefania Carrasco-Garcia; M Victoria Zelaya; Laura Bragado; Ana Olías-Arjona; Larraitz Egaña; Nicolás Samprón; Idoia Morilla; Marta Redondo-Muñoz; Mikel Rico; Massimo Squatrito; Marta Maria-Alonso; Joaquín Fernández-Irigoyen; Enrique Santamaria; Iñaki M Larráyoz; Claudia Wellbrock; Ander Matheu; Imanol Arozarena
Journal:  Cancers (Basel)       Date:  2021-01-19       Impact factor: 6.639

9.  Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.

Authors:  Lisa B E Shields; Brent J Shelton; Andrew J Shearer; Li Chen; David A Sun; Sarah Parsons; T David Bourne; Renato LaRocca; Aaron C Spalding
Journal:  Radiat Oncol       Date:  2015-10-31       Impact factor: 3.481

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.